ID
22171
Beschrijving
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Link
https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Trefwoorden
Versies (2)
- 09-05-17 09-05-17 -
- 22-05-17 22-05-17 -
Geüploaded op
22 mei 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Investigational Product Discontinuation Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Investigational Product Discontinuation Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Similar models
Investigational Product Discontinuation Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
C0457454 (UMLS CUI-2)
C0457454 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,2])